Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tabimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 8/20 | 0.65 |
| ▸ | FCER2 | P06734 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tabimorelin SCHEMBL29440097 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316837 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29899698 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL13575741 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209441 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316843 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL7982376 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL4435323 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL22345096 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29958795 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4604743-A1 | FORMULATED FOOD PRODUCTS | VitaKey Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| WO-2024086306-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024086307-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | claimed |
| WO-2023161326-A1 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-08-31 | — | — | WO | claimed |
| US-20220370471-A1 | COMPOSITION AND METHOD FOR TREATMENT OF HIPPOCAMPAL SYNAPSE DYSFUNCTION AND COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | US | claimed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1583541-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | Neuronova AB (SE) | 2005-10-12 | — | — | EP | claimed |
| EP-1258250-B1 | NERVE PROTECTIVE DRUGS | KAKEN PHARMA CO LTD (JP) | 2005-09-14 | — | — | EP | claimed |
| US-6849597-B2 | Neuroprotective drug | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-02-01 | — | — | US | claimed |
| US-20050009847-A1 | Compounds and methods for increasing neurogenesis | NEURONOVA AB (COMPANY REGISTRATION NO. 556703-0118) (SE) | 2005-01-13 | — | — | US | claimed |
| EP-1357928-A4 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2004045592-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | NEURONOVA AB (SE) | 2004-06-03 | — | — | WO | claimed |
| EP-1357928-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | New River Pharmaceuticals Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | GHSR 1226/4885FCER2 217/4885MMP9 1494/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | GHSR 639/4885FCER2 30/4885MMP9 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.